Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. (Q54569245)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Silvia Stacchiotti

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hans J. Gelderblom

2

object named as

Hans Gelderblom

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Philippe A Cassier

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Winette T van der Graaf

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Antoine Italiano

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Beatrice Seddon

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Julien Dômont

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Emanuelle Bompas

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Andrew J Wagner

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

0 references

publication date

5 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1649-1655

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21823110%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

21 January 2018

Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: A clinicopathologic and flow cytometric DNA analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation therapy for treatment of pigmented villonodular synovitis: results of a national patterns of care study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

7 January 2021

based on heuristic

inferred from DOI database lookup

Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

7 January 2021

based on heuristic

inferred from DOI database lookup

Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

7 January 2021

based on heuristic

inferred from DOI database lookup

FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26409

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54569245&oldid=2043604772"